Conference Coverage

Certolizumab Eased Skin and Joint Symptoms in PsA


 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Mease reported financial relation ships with UCB, which markets certolizumab. In addition, as a clinical trialist he has financial relationships with numerous other pharmaceutical companies that are interested in rheumatologic diseases.

Pages

Recommended Reading

Panel Recommends Tofacitinib Approval for Refractory RA
MDedge Family Medicine
Obese RA Patients Less Likely to Respond to DMARDs at 1 Year
MDedge Family Medicine
Exercise Eases Upper-Limb Dysfunction in Early RA
MDedge Family Medicine
Avoid Certain Vaccine-Biologic Combos
MDedge Family Medicine
Could a Urine Test Predict Response to Biologics?
MDedge Family Medicine
High-Dose Ustekinumab Stomps Out Palmoplantar Psoriasis
MDedge Family Medicine
RABBIT Score for Infection Risk Validated in Second Population
MDedge Family Medicine
RA Patient Feedback Suggests Criteria Fall Short
MDedge Family Medicine
Weight Contributes to Anti-TNF Response in PsA
MDedge Family Medicine
NSAIDs Retard Bone Formation In Ankylosing Spondylitis
MDedge Family Medicine